Ulisse Biomed
Provides a portable platform for rapid point-of-need genetic analysis and diagnostics.
UBM | XMIL
Overview
Corporate Details
- ISIN(s):
- IT0005451213 (+1 more)
- LEI:
- 815600F9C180B297BE35
- Country:
- Italy
- Address:
- VIA AQUILEIA, 17, 33100 UDINE
- Website:
- https://www.ulissebiomed.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Ulisse Biomed is a global biotechnology company focused on decentralizing genetic analysis and diagnostics. Its core offering is the proprietary Hyris System™, a portable, smart platform that enables rapid real-time PCR testing of biological samples in any setting. By making genetic analysis simpler and more accessible, the company facilitates the shift from centralized laboratories to point-of-need applications. Ulisse Biomed serves clients in the healthcare, diagnostics, agrifood, and nutraceutical sectors. Additionally, it provides OEM and development services for third-party kit developers and is engaged in creating innovative theranostic and therapeutic solutions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-01 17:14 |
Pre-Annual General Meeting Information
RINVIO ASSEMBLEA STRAORDINARIA IN SECONDA CONVOCAZIONE
|
Italian | 205.4 KB | ||
| 2025-11-24 23:39 |
Earnings Release
ULISSE BIOMED S.P.A. RICEVE UN ORDINE SIGNIFICATIVO PER LA FORNITURA DI PRODOTT…
|
Italian | 172.2 KB | ||
| 2025-11-21 15:31 |
Share Issue/Capital Change
SOTTOSCRITTO PER EURO 537.200 L’AUMENTO DI CAPITALE SOCIALE DELIBERATO DAL CONS…
|
Italian | 184.5 KB | ||
| 2025-11-15 12:14 |
Regulatory Filings
CONVOCAZIONE DELL’ASSEMBLEA STRAORDINARIA DEGLI AZIONISTI E DEPOSITO DELLA DOCU…
|
Italian | 200.9 KB | ||
| 2025-11-13 19:29 |
Regulatory Filings
IL CONSIGLIO DI AMMINISTRAZIONE ESERCITA LA DELEGA AD AUMENTARE IL CAPITALE SOC…
|
Italian | 242.0 KB | ||
| 2025-10-31 17:55 |
Share Issue/Capital Change
CHIUSURA OTTAVO PERIODO DI ESERCIZIO WARRANT
|
Italian | 222.3 KB | ||
| 2025-09-30 18:02 |
Share Issue/Capital Change
APERTURA DELL’OTTAVO PERIODO DI ESERCIZIO DEI “WARRANT ULISSE BIOMED S.P.A. 202…
|
Italian | 208.5 KB | ||
| 2025-09-30 17:54 |
Report Publication Announcement
IL CONSIGLIO DI AMMINISTRAZIONE DI ULISSE BIOMED APPROVA LA RELAZIONE SEMESTRAL…
|
Italian | 683.5 KB | ||
| 2025-09-05 20:05 |
Regulatory Filings
ULISSE BIOMED S.P.A. INDIVIDUA BANCA FINNAT COME INTERMEDIARIO PER LA NEGOZIAZI…
|
Italian | 207.5 KB | ||
| 2025-07-31 19:58 |
Share Issue/Capital Change
SIGNED AN INVESTMENT AGREEMENT WITH U.S. INVESTOR GLOBAL CORPORATE FINANCE
|
English | 323.4 KB | ||
| 2025-07-31 19:37 |
Share Issue/Capital Change
SOTTOSCRITTO UN ACCORDO DI INVESTIMENTO CON L’INVESTITORE STATUNITENSE GLOBAL C…
|
Italian | 540.4 KB | ||
| 2025-07-23 18:37 |
Share Issue/Capital Change
COMUNICAZIONE DI VARIAZIONE DEL CAPITALE SOCIALE
|
Italian | 255.4 KB | ||
| 2025-06-30 17:38 |
Share Issue/Capital Change
“WARRANT ULISSE BIOMED S.P.A. 2021-2026”: RISULTATI DEL SETTIMO PERIODO DI ESER…
|
Italian | 241.8 KB | ||
| 2025-05-30 12:21 |
Share Issue/Capital Change
APERTURA DEL SETTIMO PERIODO DI ESERCIZIO DEI “WARRANT ULISSE BIOMED S.P.A. 202…
|
Italian | 188.9 KB | ||
| 2025-05-12 12:02 |
Report Publication Announcement
WEBSIM INIZIA LA COPERTURA DEL TITOLO UBM
|
Italian | 181.7 KB |
Automate Your Workflow. Get a real-time feed of all Ulisse Biomed filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Ulisse Biomed
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Ulisse Biomed via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||